Post by Apellis Pharmaceuticals

C3G and primary IC-MPGN are rare, serious kidney diseases that often lead to kidney failure within 5-10 years of diagnosis. Without treatment, many patients require a kidney transplant and approximately 90% of those who receive one experience disease recurrence.    Apellis recognized the tremendous need for new treatment options – delivering the first approved treatment for patients 12 and older with these conditions. Read more about our work to transform care for patients with rare, complement-driven diseases: http://bit.ly/44NgBi9